On April 7, IsoRay Inc. (NYSE MKT: ISR) announced the first prostate cancer implant combining IsoRay’s Cesium-131 seeds with C4 Imaging’s Sirius® positive signal MRI markers. IsoRay, Inc. (NYSEMKT:ISR) shares after opening at $2.55 on last trade day and at the end of the day closed at $2.80. Company price to sales ratio in past twelve months was calculated as 32.42 and price to cash ratio as 34.36. IsoRay, Inc. (NYSEMKT:ISR) showed a negative weekly performance of -7.59%.
JAKKS Pacific, Inc. (NASDAQ:JAKK) was upgraded to “outperform” from “market perform” by analysts at BMO Capital Markets. The firm raised their price target on the shares to $10 from $8. JAKKS Pacific, Inc. (NASDAQ:JAKK) shares advanced 9.96% in last trading session and ended the day on $8.28. JAKK return on equity ratio is recorded as -34.80% and its return on assets is -11.20%. JAKKS Pacific, Inc. (NASDAQ:JAKK) yearly performance is -22.91%.
Equal Energy Ltd. (USA) (NYSE:EQU) stock is higher in last session as The proposal from Montclair gives a detailed analysis of the superiority of Equal Energy conducting a recapitalization, instead of going through with the pending sale to Petroflow Energy Corporation. The Montclair analysis came to the conclusion that the Petroflow offer undervalues Equal Energy, the sale of the company would keep investors from being a part of the company’s future potential and a levered share repurchase would give investors an immediate capital return. Equal Energy Ltd. (USA) (NYSE:EQU) shares moved up 7.09% in last trading session and was closed at $4.68, while trading in range of $4.32 – $4.80. Equal Energy Ltd. (USA) (NYSE:EQU) year to date (YTD) performance is -12.36%.
Oramed Pharmaceuticals, Inc.(NASDAQ:ORMP), announced that the Intellectual Property Department of Hong Kong has granted the Company’s patent for its invention, titled “Methods and Compositions for Oral Administrations of Proteins.” Oramed Pharmaceuticals, Inc.(NASDAQ:ORMP) weekly performance is 18.09%. On last trading day company shares ended up $13.84. Analysts mean target price for the company is $31.00.
Leave a Reply